Oramed Pharmaceuticals Inc. (ORMP) Financial Ratios
23 years of historical data (2003–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low6.3·High6.3
P/FCF
N/A
—
5yr avg: N/A
30Y Low19.6·High19.6
P/B Ratio
↓
0.85
↓-56% vs avg
5yr avg: 1.95
30Y Low0.6·High36.3
ROE
↑
37.1%
↓+724% vs avg
5yr avg: -5.9%
30Y Low-166%·High37%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ORMP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Oramed Pharmaceuticals Inc. trades at 2.7x earnings, 71% below its 5-year average of 9.2x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 88%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $164M | $121M | $99M | $94M | $469M | $560M | $72M | $58M | $74M | $115M | $91M |
| Enterprise Value | $119M | $76M | $45M | $136M | $430M | $484M | $52M | $55M | $69M | $111M | $87M |
| P/E Ratio → | 2.67 | 1.90 | — | 16.50 | — | — | — | — | — | — | — |
| P/S Ratio | 82.06 | 60.45 | — | 69.93 | 173.56 | 207.28 | 26.44 | 21.44 | 30.08 | 46.88 | 142.00 |
| P/B Ratio | 0.85 | 0.61 | 0.68 | 0.58 | 3.10 | 4.81 | 2.18 | 2.99 | 2.37 | 5.98 | 3.48 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 19.59 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 19.55 |
P/E links to full P/E history page with 30-year chart
ORMP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 37.89 | — | 101.70 | 158.92 | 178.90 | 19.35 | 20.21 | 28.04 | 45.26 | 135.90 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | 1.01 | — | 19.13 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 18.75 |
ORMP Profitability
Margins and return-on-capital ratios measuring operating efficiency
Oramed Pharmaceuticals Inc. earns an operating margin of -754.4%. Operating margins have expanded from -1176.8% to -754.4% over the past 3 years, signaling improving operational efficiency. Return on equity of 37.1% is exceptionally high.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.7% | 0.7% | — | 100.0% | 100.0% | 100.0% | 96.7% | 96.7% | 96.5% | 92.4% | 23.6% |
| Operating Margin | -754.4% | -754.4% | — | -1176.8% | -1502.0% | -896.2% | -433.8% | -541.3% | -552.3% | -438.6% | -1561.6% |
| Net Profit Margin | 3202.5% | 3202.5% | — | 412.3% | -1397.1% | -822.7% | -424.8% | -531.1% | -519.7% | -426.7% | -1710.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 37.1% | 37.1% | -12.4% | 3.5% | -28.2% | -29.8% | -44.0% | -56.8% | -50.6% | -46.1% | -43.0% |
| ROA | 33.2% | 33.2% | -10.2% | 2.9% | -26.1% | -25.8% | -29.0% | -35.0% | -29.6% | -25.7% | -31.7% |
| ROIC | -9.2% | -9.2% | -6.5% | -7.5% | -40.2% | -68.0% | -59.3% | -52.0% | -49.0% | -43.0% | -34.2% |
| ROCE | -8.4% | -8.4% | -8.1% | -9.8% | -29.3% | -30.0% | -33.9% | -40.5% | -35.4% | -29.6% | -31.2% |
ORMP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $46M exceeds total debt of $825000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.32 | 0.01 | 0.00 | 0.00 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.23 | -0.37 | 0.26 | -0.26 | -0.66 | -0.58 | -0.17 | -0.16 | -0.21 | -0.15 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -0.84 |
| Interest Coverage | — | — | -17.66 | 1.99 | — | -4037.17 | — | — | -2254.50 | -1795.17 | -910.00 |
Net cash position: cash ($46M) exceeds total debt ($825000)
ORMP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Oramed Pharmaceuticals Inc.'s current ratio of 6.98x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.06x to 6.98x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.98 | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 | 6.28 | 6.82 | 3.93 | 8.62 |
| Quick Ratio | 6.98 | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 | 6.28 | 6.82 | 3.93 | 8.62 |
| Cash Ratio | 6.60 | 6.60 | 24.97 | 3.05 | 27.10 | 14.09 | 8.80 | 6.08 | 6.69 | 3.90 | 8.57 |
| Asset Turnover | — | 0.01 | — | 0.01 | 0.02 | 0.02 | 0.06 | 0.08 | 0.05 | 0.06 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 846.07 | — | — | — | — | — | — | — | — | — |
ORMP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Oramed Pharmaceuticals Inc. returns 2.9% to shareholders annually primarily through share buybacks. The earnings yield of 37.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 37.4% | 52.6% | — | 6.1% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 5.1% |
| Buyback Yield | 2.9% | 3.9% | 2.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.9% | 3.9% | 2.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $42M | $41M | $41M | $39M | $28M | $21M | $17M | $15M | $13M | $13M |
Peer Comparison
Compare ORMP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ORMPYou | $164M | 2.7 | — | — | 0.7% | -754.4% | 37.1% | -9.2% | — |
 MNKD | $1B | 194.5 | 31.3 | 87.8 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 NRXP | $67M | -2.9 | — | — | 58.8% | -1324.4% | — | — | — |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 NVO | $204B | 13.0 | 9.6 | 46.0 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 LLY | $1.0T | 48.1 | 34.5 | 116.2 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 SNY | $101B | 18.0 | 10.7 | 9.9 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 VKTX | $4B | -10.1 | — | — | — | — | -47.3% | -44.4% | — |
 AMGN | $186B | 24.2 | 14.6 | 23.0 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 BMY | $112B | 15.9 | 9.0 | 8.7 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 PFE | $143B | 18.4 | 10.3 | 15.7 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ORMP — Frequently Asked Questions
Quick answers to the most common questions about buying ORMP stock.
What is Oramed Pharmaceuticals Inc.'s P/E ratio?
Oramed Pharmaceuticals Inc.'s current P/E ratio is 2.7x. The historical average is 9.2x. This places it at the 50th percentile of its historical range.
What is Oramed Pharmaceuticals Inc.'s ROE?
Oramed Pharmaceuticals Inc.'s return on equity (ROE) is 37.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -51.1%.
Is ORMP stock overvalued?
Based on historical data, Oramed Pharmaceuticals Inc. is trading at a P/E of 2.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Oramed Pharmaceuticals Inc.'s profit margins?
Oramed Pharmaceuticals Inc. has 0.7% gross margin and -754.4% operating margin.